|
Tuesday 4th October 2022 |
Text too small? |
Cannasouth Limited (NZX: CBD ) is pleased to announce that it has received its first shipment of verified cannabis medicines.
Cannasouth CEO Mark Lucas says, “This accomplishment marks the end of a near two-year process since submitting product assessments with the Medicinal Cannabis Agency.
"The differentiated formulations of our products will provide New Zealand patients and prescribers with new treatment options compared to existing products on the New Zealand market. We are confident these products offer patients and prescribers a point of difference to meet the treatment needs of a wider range of conditions.”
Navigating and establishing the supply chain for its first medicines means Cannasouth is now generating revenue from the sale of medicines in New Zealand.
A list of all medicinal cannabis products that meet the New Zealand minimum quality standard can be found here: https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicinal-cannabis-agency/medicinal-cannabis-agency-information-health-professionals/medicinal-cannabis-products-meet-minimum-quality-standard
-ENDS-
NXZ MAP_First Verified Cannabis Medicines Received
No comments yet
PYS - PaySauce to announce F26 full year results on 27 May 2026
PEB - Draft LCD Proposes Medicare Coverage for Triage and Triage
MEL - Meridian Energy monthly operating report for April 2026
FBU - Sale of South Australian property
AIR - Air New Zealand market update
May 14th Morning Report
PEB - Pacific Edge Placement Increased to NZ$25.4 Million
Radius Care Reports Earnings Growth and 50% Higher Dividend
May 13th Morning Report
Pacific Edge launches capital raise of NZ$24 million